ArticleJournal of the American Academy of Dermatology2025
The effect of isotretinoin treatment for acne vulgaris on height in adolescents: A retrospective cohort study using the Rochester Epidemiology Project.
Article in Journal of the American Academy of Dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIsotretinoin is the first-line treatment for severe acne, but its effects on adolescent growth remain unclear.
objectiveTo assess the effects of isotretinoin on final adult height and height velocity in adolescents treated for acne.
methodsThis retrospective cohort study used the Rochester Epidemiology Project to identify patients diagnosed with acne between 2005 and 2021 who initiated isotretinoin or oral antibiotics before age 15. Height velocity was calculated using measurements taken within 1 year pre- and postmedication initiation, and final height was recorded at 18 years. Multivariable regression models adjusted for age and sex.
resultsAmong 226 patients treated with isotretinoin and 1179 controls, final height did not differ significantly between groups (-0.67 cm; CI: -2.21 to 0.87). However, patients treated with isotretinoin had a lower postmedication initiation height velocity (-0.12 cm/month; CI: -0.21 to -0.04, P = .005) and a greater reduction in post- versus premedication initiation height velocity (-0.31 cm/month; CI: -0.54 to -0.07, P = .011). No significant dosage effects were observed. LIMITATIONS: The study was limited by sample size, potential unmeasured confounders, and a predominantly non-Hispanic white population.
conclusionsWhile isotretinoin may reduce height velocity, it is not associated with negative effects on final adult height among adolescents treated for acne.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.